Evotec SE (EVO)
NASDAQ: EVO · Real-Time Price · USD
4.400
+0.520 (13.40%)
Nov 4, 2024, 4:00 PM EST - Market closed

Company Description

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide.

The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health.

It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as collaboration with CHDI Foundation, Inc.; and a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic, as well as research collaboration with Pfizer for metabolic and infectious diseases.

The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Evotec SE
Evotec SE logo
Country Germany
Founded 1993
IPO Date Nov 4, 2021
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 5,061
CEO Christian Wojczewski

Contact Details

Address:
Essener Bogen 7
Hamburg, 22419
Germany
Phone 49 40 560 81 0
Website evotec.com

Stock Details

Ticker Symbol EVO
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency EUR
IPO Price $26.16
CIK Code 0001412558
CUSIP Number 30050E105
ISIN Number US30050E1055
SIC Code 2834

Key Executives

Name Position
Dr. Christian Wojczewski Chief Executive Officer
Laetitia Rouxel Chief Financial Officer and Member of Management Board
Dr. Cord Dohrmann Ph.D. Chief Scientific Officer and Member of Management Board
Dr. Craig Johnstone Ph.D. Chief Operating Officer and Member of Management Board
Aurelie Dalbiez Chief People Officer and Member of Management Board
Anja Bosler Principal Accounting Officer and Senior Vice President of Group Accounting
Volker Braun Executive Vice President and Head of Global Investor Relations and ESG
Dr. Christian Dargel Executive Vice President Global Head of Legal and Compliance
Gabriele Hansen Senior Vice President and Head of Global Corporate Communications & Marketing
Dr. Ian M. Hunneyball Senior Vice President of Programme Management and Clinical Operations

Latest SEC Filings

Date Type Title
Aug 14, 2024 6-K Report of foreign issuer
Aug 14, 2024 20-F Annual and transition report of foreign private issuers
Aug 6, 2024 6-K Report of foreign issuer
Jun 10, 2024 6-K Report of foreign issuer
May 22, 2024 6-K Report of foreign issuer
Apr 30, 2024 NT 20-F Notification of inability to timely file Form 20-F
Apr 24, 2024 6-K Report of foreign issuer
Apr 23, 2024 6-K Report of foreign issuer
Apr 8, 2024 6-K Report of foreign issuer
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals